Literature DB >> 32467967

Digital phenotyping of negative symptoms: the relationship to clinician ratings.

Alex S Cohen1,2, Elana Schwartz1,2, Thanh P Le1,2, Tovah Cowan1,2, Brian Kirkpatrick3, Ian M Raugh4, Gregory P Strauss4.   

Abstract

Negative symptoms are a critical, but poorly understood, aspect of schizophrenia. Measurement of negative symptoms primarily relies on clinician ratings, an endeavor with established reliability and validity. There have been increasing attempts to digitally phenotype negative symptoms using objective biobehavioral technologies, eg, using computerized analysis of vocal, speech, facial, hand and other behaviors. Surprisingly, biobehavioral technologies and clinician ratings are only modestly inter-related, and findings from individual studies often do not replicate or are counterintuitive. In this article, we document and evaluate this lack of convergence in 4 case studies, in an archival dataset of 877 audio/video samples, and in the extant literature. We then explain this divergence in terms of "resolution"-a critical psychometric property in biomedical, engineering, and computational sciences defined as precision in distinguishing various aspects of a signal. We demonstrate how convergence between clinical ratings and biobehavioral data can be achieved by scaling data across various resolutions. Clinical ratings reflect an indispensable tool that integrates considerable information into actionable, yet "low resolution" ordinal ratings. This allows viewing of the "forest" of negative symptoms. Unfortunately, their resolution cannot be scaled or decomposed with sufficient precision to isolate the time, setting, and nature of negative symptoms for many purposes (ie, to see the "trees"). Biobehavioral measures afford precision for understanding when, where, and why negative symptoms emerge, though much work is needed to validate them. Digital phenotyping of negative symptoms can provide unprecedented opportunities for tracking, understanding, and treating them, but requires consideration of resolution.
© The Author(s) 2020. Published by Oxford University Press on behalf of the Maryland Psychiatric Research Center. All rights reserved. For permissions, please email: journals.permissions@oup.com.

Entities:  

Keywords:  biobehavioral; computational; deficit; digital phenotyping; negative; psychiatry; schizophrenia

Year:  2021        PMID: 32467967      PMCID: PMC7825094          DOI: 10.1093/schbul/sbaa065

Source DB:  PubMed          Journal:  Schizophr Bull        ISSN: 0586-7614            Impact factor:   9.306


  47 in total

1.  Whither Research Domain Criteria (RDoC)?: The Good, the Bad, and the Ugly.

Authors:  Daniel R Weinberger; Ira D Glick; Donald F Klein
Journal:  JAMA Psychiatry       Date:  2015-12       Impact factor: 21.596

2.  The NIMH-MATRICS consensus statement on negative symptoms.

Authors:  Brian Kirkpatrick; Wayne S Fenton; William T Carpenter; Stephen R Marder
Journal:  Schizophr Bull       Date:  2006-02-15       Impact factor: 9.306

3.  A laboratory-based procedure for measuring emotional expression from natural speech.

Authors:  Alex S Cohen; Kyle S Minor; Gina M Najolia; S Lee Hong
Journal:  Behav Res Methods       Date:  2009-02

4.  Video-based quantification of body movement during social interaction indicates the severity of negative symptoms in patients with schizophrenia.

Authors:  Zeno Kupper; Fabian Ramseyer; Holger Hoffmann; Samuel Kalbermatten; Wolfgang Tschacher
Journal:  Schizophr Res       Date:  2010-08       Impact factor: 4.939

5.  The Schedule for the Deficit syndrome: an instrument for research in schizophrenia.

Authors:  B Kirkpatrick; R W Buchanan; P D McKenney; L D Alphs; W T Carpenter
Journal:  Psychiatry Res       Date:  1989-11       Impact factor: 3.222

6.  The Clinical Assessment Interview for Negative Symptoms (CAINS): final development and validation.

Authors:  Ann M Kring; Raquel E Gur; Jack J Blanchard; William P Horan; Steven P Reise
Journal:  Am J Psychiatry       Date:  2013-02       Impact factor: 18.112

7.  Periods of recovery in deficit syndrome schizophrenia: a 20-year multi-follow-up longitudinal study.

Authors:  Gregory P Strauss; Martin Harrow; Linda S Grossman; Cherise Rosen
Journal:  Schizophr Bull       Date:  2008-12-18       Impact factor: 9.306

8.  A multisite investigation of the reliability of the Scale for the Assessment of Negative Symptoms.

Authors:  K T Mueser; S L Sayers; N R Schooler; R M Mance; G L Haas
Journal:  Am J Psychiatry       Date:  1994-10       Impact factor: 18.112

9.  Avolition in schizophrenia is associated with reduced willingness to expend effort for reward on a Progressive Ratio task.

Authors:  Gregory P Strauss; Kayla M Whearty; Lindsay F Morra; Sara K Sullivan; Kathryn L Ossenfort; Katherine H Frost
Journal:  Schizophr Res       Date:  2015-12-14       Impact factor: 4.939

10.  The Latent Structure of Negative Symptoms in Schizophrenia.

Authors:  Gregory P Strauss; Alicia Nuñez; Anthony O Ahmed; Kimberly A Barchard; Eric Granholm; Brian Kirkpatrick; James M Gold; Daniel N Allen
Journal:  JAMA Psychiatry       Date:  2018-12-01       Impact factor: 21.596

View more
  7 in total

1.  Machine Learning Identifies Digital Phenotyping Measures Most Relevant to Negative Symptoms in Psychotic Disorders: Implications for Clinical Trials.

Authors:  Sayli M Narkhede; Lauren Luther; Ian M Raugh; Anna R Knippenberg; Farnaz Zamani Esfahlani; Hiroki Sayama; Alex S Cohen; Brian Kirkpatrick; Gregory P Strauss
Journal:  Schizophr Bull       Date:  2022-03-01       Impact factor: 9.306

2.  Natural Language Processing and Psychosis: On the Need for Comprehensive Psychometric Evaluation.

Authors:  Alex S Cohen; Zachary Rodriguez; Kiara K Warren; Tovah Cowan; Michael D Masucci; Ole Edvard Granrud; Terje B Holmlund; Chelsea Chandler; Peter W Foltz; Gregory P Strauss
Journal:  Schizophr Bull       Date:  2022-09-01       Impact factor: 7.348

3.  Revisiting how People with Schizophrenia Spend Their Days: Associations of lifetime milestone Achievements with Daily Activities examined with Ecological Momentary Assessment.

Authors:  Michelle M Perez; Bianca A Tercero; Fiorella Durand; Felicia Gould; Raeanne C Moore; Colin A Depp; Robert A Ackerman; Amy E Pinkham; Philip D Harvey
Journal:  Psychiatry Res Commun       Date:  2022-06-26

4.  Geolocation as a Digital Phenotyping Measure of Negative Symptoms and Functional Outcome.

Authors:  Ian M Raugh; Sydney H James; Cristina M Gonzalez; Hannah C Chapman; Alex S Cohen; Brian Kirkpatrick; Gregory P Strauss
Journal:  Schizophr Bull       Date:  2020-12-01       Impact factor: 9.306

5.  Digital phenotyping adherence, feasibility, and tolerability in outpatients with schizophrenia.

Authors:  Ian M Raugh; Sydney H James; Cristina M Gonzalez; Hannah C Chapman; Alex S Cohen; Brian Kirkpatrick; Gregory P Strauss
Journal:  J Psychiatr Res       Date:  2021-04-30       Impact factor: 5.250

6.  Efficacy and Safety of Roluperidone for the Treatment of Negative Symptoms of Schizophrenia.

Authors:  Michael Davidson; Jay Saoud; Corinne Staner; Nadine Noel; Sandra Werner; Elisabeth Luthringer; David Walling; Mark Weiser; Philip D Harvey; Gregory P Strauss; Remy Luthringer
Journal:  Schizophr Bull       Date:  2022-05-07       Impact factor: 7.348

7.  Validating Biobehavioral Technologies for Use in Clinical Psychiatry.

Authors:  Alex S Cohen; Christopher R Cox; Raymond P Tucker; Kyle R Mitchell; Elana K Schwartz; Thanh P Le; Peter W Foltz; Terje B Holmlund; Brita Elvevåg
Journal:  Front Psychiatry       Date:  2021-06-11       Impact factor: 4.157

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.